PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe doses of PTK 787
(vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous
Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic
Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is.